The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

Bamlanivimab, a monoclonal antibody targeting the spike protein of severe acute respiratory syndrome coronavirus 2, is available for ambulatory treatment of coronavirus disease 2019 (COVID-19). This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency...

Descripción completa

Detalles Bibliográficos
Autores principales: Corwin, Douglas S, Ender, Peter T, Sahu, Nitasa, Durgham, Ryan A, McGorry, Dennis M, Rahman, Awan, Stoltzfus, Jill, Jahre, Jeffrey A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272954/
https://www.ncbi.nlm.nih.gov/pubmed/34258324
http://dx.doi.org/10.1093/ofid/ofab305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272954/
https://www.ncbi.nlm.nih.gov/pubmed/34258324
http://dx.doi.org/10.1093/ofid/ofab305

Ejemplares similares